However, we cannot rule out the possibility that loss of transcription factor expression, such as CCAAT enhancer binding protein beta (C/EBPβ)71, 72 or peroxisome proliferator‐activated receptor gamma (PPARγ),73, 74 may also play a role in reduced G0S2 expression during CML disease progression and TKI resistance. This evidence concerns the gene CEBPB and chronic myelogenous leukemia, BCR-ABL1 positive.